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Overview
Gestational diabetes mellitus (GDM) refers to hyper  gly­
cemia that first presents during pregnancy and typically 
resolves itself post­partum. There are inadequate data on 
the  prevalence  of  GDM;  however,  in  1988  it  was  esti­
mated that about 4% of pregnancies in the United States 
were complicated by diabetes, with 88% of these accoun­
ted for by GDM [1]. More recent data suggest that, as 
with the overall increased prevalence of diabetes, rates of 
GDM are significantly increasing [2]. For exam  ple, Dabelea 
and colleagues [3] examined trends in singleton pregnan­
cies  from  the  Kaiser  Permanente  health  mainte  nance 
organization  of  Colorado  between  1994  and  2002  and 
noted that rates of GDM increased two­fold in all ethnic 
groups. Accurate data on the prevalence and inci  dence of 
GDM are likely to become available given that screening 
during pregnancy is almost routine and consis  tent diag­
nostic criteria are now being implemented [4].
Hyperglycemia  during  pregnancy,  whether  due  to 
GDM  or  other  forms  of  diabetes,  has  implications  for 
mother, developing fetus, and child. Women diagnosed 
with GDM have a higher risk for future type 2 diabetes 
mellitus  (T2DM)  [5].  Kjos  et  al.  [6]  were  the  first  to 
demonstrate that this risk was even higher in Hispanic 
women with previous GDM by showing that 45% of a 
cohort  followed  for  5  years  post­partum  developed 
T2DM despite plasma glucose returning to non­diabetic 
levels. The observation that previous GDM increases risk 
for future T2DM was subsequently confirmed in other 
ethnic groups [7]. Women with GDM have a higher rate 
of caesarean section, gestational hypertension, and large 
for gestational age deliveries [8]. Maternal diabetes has 
been  shown  to  be  associated  with  increased  risk  for 
macro  somia  [8,9],  and  GDM­associated  macrosomia  is 
associated  with  increased  rates  of  a  variety  of  compli­
cations, including hypoglycemia and respiratory distress 
syndrome [10].
Pettitt et al. [11] were among the first to show the asso­
ciation between maternal hyperglycemia and increased 
risk for babies large for their gestational age or macro­
somia,  with  implications  for  additional  morbidities  in 
adulthood [12]. For example, Pima Indian women whose 
birth weight was over 4,500 g had a four­fold higher risk 
of  developing  GDM  when  they  became  pregnant  as 
adults  [12].  Also,  in  siblings  born  from  pregnancies 
discor  dant for diabetes, but who were raised in similar 
environments, the sibling born from the diabetic preg­
nancy was more obese than the sibling born from the 
non­diabetic pregnancy [13].
New insights into pregnancy­related outcomes are now 
becoming available from the Hyperglycemia and Adverse 
Pregnancy  Outcome  (HAPO)  study  [14].  HAPO  is  a 
prospective observational study of over 25,000 pregnant 
women in nine countries who underwent an oral glucose 
tolerance test (OGTT; 75 g glucose administered orally, 
followed by blood sampling at 2 hours) at 24 to 32 weeks 
of  gestation,  with  assessment  of  several  maternal  and 
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some new insights into the management of GDM [15] 
and has shown that body mass index (BMI), independent 
of glycemia, was associated with the frequency of excess 
fetal  growth  and  pre­eclampsia  [16].  The  HAPO  study 
should provide many new insights into the relationship 
between maternal hyperglycemia and pregnancy­related 
outcomes.
Here, I review the current state of knowledge regarding 
genetic susceptibility to T2DM and its implications for 
GDM. The physiological implications of mutations under­
lying monogenic forms of diabetes and polymorphisms 
underlying complex forms of diabetes are also considered 
(Table  1).  The  issue  of  whether  GDM  and  T2DM  are 
distinct  diseases  and  whether  genetic  information  can 
shed additional light on this controversy are discussed. 
Finally, a brief discussion of the clinical implications of 
genetic variation is provided.
The role of genetics
Evidence for a genetic basis
The study of genetics in GDM has been relatively lacking 
until  the  recent  advent  of  genome­wide  association 
(GWA) studies (see below). Such studies have been partly 
hampered by the lack of evidence for a genetic basis for 
GDM.  That  is  not  to  say  that  GDM  does  not  have  a 
genetic  basis,  but  that  the  ability  to  accurately  assess 
familiality of GDM is limited. Twin concordance rates, 
familial risk estimates, or heritability studies have been 
used to provide evidence of a genetic basis for a given 
phenotype.  Prospective  studies  are  complicated  by  the 
need to study related individuals presenting with GDM, a 
very daunting task. Retrospective studies are also fraught 
with difficulties. The diagnostic criteria for GDM have 
changed over the years [4,17­20], complicating retro  spec­
tive identification of GDM cases. Screening for GDM has 
not been a part of routine medical care until recently. 
These factors can lead to ascertainment bias and poor 
estimates of heritability. Finally, the very low prevalence 
of GDM, relative to the population and to other forms of 
diabetes,  makes  it  difficult  to  accumulate  sufficient 
samples for genetic studies.
Several studies have examined clustering of GDM with 
either type 1 or type 2 diabetes. For example, McLellan 
and colleagues [21] identified 14 women with a previous 
diagnosis of GDM with both parents available for study 
and noted that glucose intolerance was observed in 64% 
of the parents. Similarly, Martin et al. [22] showed that a 
higher than expected number of mothers with diabetes 
was observed in 91 women with GDM. These and other 
similar studies hint at the possibility of common genetic 
determinants for GDM, although the effect of in utero 
hyperglycemia  on  offspring  with  implications  in  adult­
hood cannot be discounted. We reported an estimated 
sibling risk ratio for GDM of 1.75, which was based on 
state­wide medical record information from the state of 
Washington  [23].  Although  this  estimate  suggests  an 
increased  sibling  risk  for  GDM,  it  is  likely  this  is  an 
underestimate of the true risk given the methodological 
complications noted above.
Glucokinase
For  a  good  description  of  candidate  gene  studies  for 
GDM, see a recent review by Robitaille and Grant [24]. 
One issue regarding early genetic associations is that they 
rarely replicated across studies, partly owing to the fact 
that gene effects are relatively small and most candidate 
gene  studies  were  under­powered.  However,  studies  of 
monogenic forms of diabetes, specifically maturity­onset 
diabetes of the young 2 (MODY2), provided some of the 
first insights into the contribution of genetic variation to 
hyperglycemia  observed  during  pregnancy  and  fetal 
outcomes.  MODY2  is  an  autosomal  dominant  form  of 
MODY due to mutations in glucokinase (GCK) [25­27]. 
Table 1. Characteristics and treatment modalities of different forms of diabetes mellitus
Characteristics Treatment modalities
MODY A series of autosomal dominant forms of diabetes. Mutations in genes 
predisposing to six different forms of MODY have been identified. 
MODY2, which results from mutations in glucokinase (GCK), is unique 
among MODYs in that it results in modest hyperglycemia that does 
not require pharmacological intervention. MODY is characterized by 
β-cell dysfunction in the absences of insulin resistance or obesity
MODY1, MODY3 and MODY4 are typically treated by oral 
hypoglycemics. MODY5 and MODY6 are typically treated using insulin 
therapy. MODY2 can be managed by lifestyle modification alone
GDM Hyperglycemia that presents during pregnancy and typically resolves 
itself post-partum. GDM is characterized by insulin resistance and 
β-cell dysfunction. Women with previous GDM are at high risk for 
future T2DM 
Lifestyle modification is the first choice to manage GDM. However, 
if glycemic control cannot be achieved, then pharmacological 
intervention, primarily insulin therapy, can be implemented
T2DM The predominant form of diabetes characterized by insulin resistance 
and β-cell dysfunction, typically accompanied by obesity
Lifestyle modification is recommended in all cases, but in most 
circumstances pharmacological intervention is required. Choice of 
therapies includes oral hypoglycemics, metformin, thiazolidinediones, 
GLP1 mimetics, and DPP-IV inhibitors. Combination therapy has also 
become more common in the management of T2DM
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observed in patients with MODY2 mutations is due to a 
rightward shift in the insulin secretory dose response to 
glucose [27]. This rightward shift indicates that MODY2 
patients can dynamically respond to glycemic excursions, 
but at a higher glucose set point. Thus, MODY2 patients 
are typically treated by lifestyle modification and remain 
modestly  hyperglycemic  relative  to  the  non­diabetic 
population.
Early evidence suggested that females with GCK muta­
tions frequently presented with GDM, as suggested by 
the  observation  that  7  of  11  parous  women  from  two 
pedigrees with a specific GCK mutation were diagnosed 
with GDM [28,29]. Hattersley and colleagues [30] posited 
that the association between low birth weight and subse­
quent  insulin  resistance  in  adulthood  is  genetically 
determined, presumably a result of GCK mutations, and 
introduced  the  ‘fetal  insulin’  hypothesis.  An  important 
component  to  this  hypothesis  is  that  low  insulin­
mediated fetal growth in utero is determined by a defect 
in glucose sensing by the pancreas due to GCK mutations, 
resulting in reduced insulin levels during critical periods 
of growth and development of the fetus. In partial support 
of this hypothesis, they showed [30] that maternal hyper­
glycemia due to GCK mutations was associated with an 
increased birth weight that was a consequence of additive 
effects  of  the  maternal  and  the  fetal  GCK  genotype 
(Figure 1). They further showed [31] that in sibling pairs 
discordant for GCK mutations, the sibling with the GCK 
mutation  had  a  lower  birth  weight  than  the  sibling 
without the mutation. They proposed that differences in 
birth  weight  in  their  sample  were  a  consequence  of  a 
direct  effect  of  fetal  GCK  mutations  on  fetal  insulin 
secretion  and  an  indirect  effect  of  maternal  hypergly­
cemia due to GCK mutations in the mothers.
It should be noted that common variants in GCK also 
seem  to  contribute  to  maternal  hyperglycemia  that 
subsequently  affects  birth  weight.  A  large­scale  meta­
analysis  confirmed  observations  from  previous  studies 
that the ­30 promoter variant in GCK (rs1799884) was 
associated  with  both  fasting  glucose  and  birth  weight 
[32,33]. The presence of at least one copy of the maternal 
A  allele  increased  birth  weight  by  an  average  of  64  g 
compared with G/G homozygous individuals, with weak 
evidence for an additive effect of the maternal A allele 
[32].  Furthermore,  analysis  of  a  subset  of  the  data 
suggested that the effect of rs1799884 on fasting glucose 
partly  explains  the  association  with  birth  weight.  Fetal 
genotype  information  was  available  on  a  subset  of  the 
data, but this study [32] was not able to demonstrate any 
interaction between maternal and fetal GCK genotypes.
T2DM susceptibility loci and GDM
The introduction of GWA has transformed the study of 
complex  disease  genetics  and  GWA  studies  of  T2DM 
have  been  at  the  forefront  of  this  new  era  of  human 
genetics. Only three T2DM susceptibility loci had been 
identified before 2007: two identified by candidate gene 
analysis  [34,35]  and  one  by  fine­mapping  of  a  linkage 
signal [36]. GWA meta­analyses of T2DM and of T2DM­
related quantitative traits have resulted in identification 
of 38 T2DM susceptibility loci so far; most have been 
identified within the past 3 years [37­50]. The assembly of 
ever  larger  samples  coupled  with  the  increasing  appli­
cation of whole genome sequencing will probably identify 
additional susceptibility loci. However, even the currently 
known  loci  have  illuminated  new  biology  under  lying 
T2DM,  such  as  MTNR1B  (encoding  a  member  of  the 
mela  tonin receptor family) [45,46] and CRY2 (encoding a 
member of the cryptochrome family that regulates the 
clock  gene)  [49],  which  point  to  regulation  of  ‘clock’ 
genes and circadian rhythms as contributing to T2DM 
pathogenesis.
How  has  the  discovery  of  T2DM  susceptibility  loci 
contri  buted to our understanding of the genetics of GDM? 
Two groups have examined whether T2DM suscep  tibility 
loci  identified  by  GWA  are  also  associated  with  GDM 
[51,52].  Cho  et  al.  [52]  examined  18  single  nucleo  tide 
polymorphisms (SNPs) in nine T2DM suscep  ti  bility loci 
and  tested  them  for  association  with  GDM  in  a  large 
Figure 1. Effect of maternal and fetal GCK genotype on birth 
weight (mean ± SD). Birth weight decreases as a function of the 
presence (plus sign) or absence (minus sign) of GCK mutations in the 
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protein of unknown function but having high sequence 
homology  with  proteins  regulating  cyclin­dependent 
kinase 5, and CDKN2A and CDKN2B, two genes involved 
in cell cycle regulation, all showed strong evidence for 
association with GDM. Interestingly, the odds ratios for 
GDM were slightly higher (about 1.5) than the odds ratio 
of about 1.2 typically observed for T2DM. One possible 
reason for the larger effect size in this study may be the 
fact  that  the  control  group  consisted  of  non­diabetic 
individuals of both sexes. Alternatively, these specific loci 
may make a larger contribution to the genetic risk for 
GDM  than  for  T2DM.  Other  loci,  HHEX  (encoding  a 
transcription  factor  involved  in  development  of  the 
ventral pancreas and possibly the liver), IGF2BP2 (encod­
ing  a  protein  that  binds  to  the  5’­UTR  of  insulin­like 
growth  factor­2  mRNA  and  that  may  regulate  transla­
tion),  SLC30A8  (encoding  a  zinc  transporter  found  on 
insulin secretory vesicles), and TCF7L2 (encoding a trans­
cription factor), showed modest evidence for associa  tion 
with  GDM,  with  P­values  ranging  between  0.038  and 
0.003. The odds ratios for risk for GDM across these loci 
were similar to those observed for T2DM.
Similar to the study of Cho et al. [52], Lauenborg and 
colleagues  [51]  examined  the  association  between  11 
T2DM susceptibility loci for association with GDM in a 
Danish  case­control  sample.  In  their  study  [51],  only 
TCF7L2  showed  strong  evidence  for  association  with 
GDM,  with  an  odds  ratio  similar  to  that  observed  for 
T2DM.  Two  additional  loci,  CDKAL1  and  HNF1B 
(encod  ing  a  member  of  the  homeodomain­containing 
family of transcription factors), showed marginal associa­
tion  with  GDM.  They  subsequently  derived  an  allelic 
score for each individual by counting up the number of 
‘risk’ alleles carried by each individual across the 11 loci 
and showed a difference in distribution of these allelic 
scores when comparing GDM with non­GDM women. 
Overall,  they  estimated  the  odds  ratio  for  GDM  to  be 
1.18 per allele in their sample after adjusting for age and 
BMI. Also, there was a 3.3­fold increased risk for GDM 
when they compared women carrying fewer than nine 
risk alleles with those carrying more than 15 risk alleles. 
Lauenborg et al. [51] then tested whether these 11 loci can 
be used to predict GDM by comparing various logistic­
regression­based models, assuming the 11 loci worked in 
an additive manner, and computing the receiver­operator 
curve (ROC) area under the curve (AUC) as a metric of 
accuracy.  Age  and  BMI  alone  had  an  AUC  of  0.68, 
suggesting a relatively poor ability to predict GDM. The 11 
T2DM susceptibility loci had an AUC of 0.62, which was 
similar to the model with age and BMI alone. The AUC 
increased to 0.73 when the two were combined.
There are important points to be noted from the ROC 
results.  First,  not  surprisingly,  age  and  BMI  alone  are 
inadequate  for  discriminating  GDM,  suggesting  that 
other clinical variables, such as the OGTT [4,53], may 
provide better discrimination. Second, many would view 
the near equivalent AUC between the non­genetic and 
genetic models as evidence for a lack of a genetic basis for 
GDM,  but  it  should  be  noted  that  comparison  across 
models used for ROC analysis cannot be used to assess 
whether a phenotype has a genetic basis or not. Further­
more, it is important to remember that these are known 
T2DM  susceptibility  loci  and  not  necessarily  suscepti­
bility loci for GDM. Thus, there is no a priori reason that 
these  loci  should  provide  adequate  discrimination  of 
GDM. Finally, the genetic variants identified by GWA are 
only  landmarks  indicating  the  possible  presence  of  a 
T2DM susceptibility variant. Additional work is neces­
sary to identify the functional variant responsible for the 
increased T2DM risk and, once those variants are identi­
fied, it is possible the performance of genetic models may 
improve.
Implications for family members
The studies by Cho et al. [52] and Lauenborg et al. [51] 
suggest that GDM does not have a unique genetic pre­
disposition and, at a minimum, that there is some overlap 
in  genetic  susceptibility  to  GDM  and  T2DM.  This,  of 
course,  does  not  exclude  the  possibility  that  there  are 
some loci uniquely contributing to the risk for GDM. The 
overlap in genetic susceptibility may partly explain the 
increased risk for T2DM in women with previous GDM 
[5­7]. Given this observation, an important question is 
what the implication is for family members of a woman 
with previous GDM.
There are precious few family­based studies of diabetes 
and  even  fewer  studies  examining  critical  diabetes 
pheno  types,  given  the  shift  to  GWA  studies  based  on 
case­control  samples.  Although  there  are  family­based 
studies of T2DM in Hispanics [54­63], so far none are 
examining  interactions  among  genes  or  with  environ­
mental exposures. Furthermore, only the Insulin Resistance 
Atherosclerosis  Study  Family  Study  [54]  has  direct 
measures of insulin resistance and insulin secretion, in 
their  case  based  on  frequently  sampled  intravenous 
glucose  tolerance  test  (FSIGT)  with  Minimal  Model 
analysis [64,65]. Other studies rely on indirect measures 
of these critical T2DM­related phenotypes. Furthermore, 
these  family­based  samples  are  ascertained  on  T2DM 
and not GDM.
The BetaGene study has hypothesized that genetic loci 
underlying susceptibility to GDM have implications for 
family  members  and  has  been  studying  the  genetics 
underlying T2DM­related quantitative traits in Mexican 
American  families  of  probands  with  or  without  a 
previous diagnosis of GDM [66­69]. BetaGene has two 
unique  characteristics  compared  with  other  genetic 
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analysis  of  T2DM­related  quantitative  traits,  believing 
that understanding the biological effects of genetic varia­
tion may illuminate key components of the pathogenesis 
of  GDM  and  T2DM.  Second,  a  large  subset  of  the 
BetaGene participants have undergone detailed pheno­
typing, including dual energy X­ray absorptiometry for 
body  composition  and  FSIGT  with  Minimal  Model 
analysis to estimate insulin sensitivity and insulin secre­
tion, given the focus on quantitative traits. To my know­
ledge, BetaGene is the only family­based genetic study 
ascertained on GDM in the world, as of this writing.
The BetaGene study has shown associations between 
some T2DM susceptibility loci and T2DM­related quanti­
tative traits [66,68,69], but more importantly it has shown 
that  these  associations  are  modified  by  other  factors, 
such  as  adiposity  or  other  gene  variants.  For  example, 
variation in TCF7L2 is one of the most highly replicated 
T2DM susceptibility loci. BetaGene was the first to show 
that variation in TCF7L2 was associated with GDM [66], 
an observation replicated by others [70]. BetaGene also 
showed  that  the  association  between  TCF7L2  and 
OGTT­based insulin secretion is modified by total body 
fat  [66].  A  similar  modifying  effect  on  the  association 
between TCF7L2 and β­cell function as represented by 
the disposition index, a measure of β­cell function [65], 
was  also  observed.  An  interesting  observation  of  this 
modifying effect of adiposity is that individuals carrying 
the  T2DM  ‘risk’  allele  have  a  ‘better’  trait  value  than 
individuals carrying the ‘non­risk’ allele in the low body 
fat range, but this relationship flips in the high body fat 
range.
Figure 2 uses IGF2BP2 as an example of this pheno­
menon. This figure shows the IGF2BP2 genotype­specific 
insulin sensitivity (mean ± standard deviation (SD)) in 
the lowest and highest tertiles of body fat in BetaGene 
participants  [68].  Here,  ‘risk’  allele  refers  to  the  allele 
conferring  risk  for  T2DM  as  determined  by  the  initial 
series  of  GWA  studies  [37­39].  Insulin  sensitivity 
decreases with each copy of the T2DM risk allele within 
the highest body fat tertile, which ranged from 38.9% to 
54%  body  fat.  This  is  an  expected  pattern,  given  that 
insulin resistance is a hallmark of T2DM and one might 
expect  that  individuals  carrying  T2DM  susceptibility 
variants might be insulin resistant compared with non­
carriers. However, a counterintuitive pattern is observed 
within the lowest body fat tertile (range 8.7 to 31.7% body 
fat), where insulin sensitivity increases with each copy of 
the  T2DM  risk  allele.  This  observation  suggests  a 
different biological effect of the T2DM ‘risk’ allele in the 
low compared with the high adiposity range.
The  modifications  of  these  genetic  associations  by 
adiposity can be viewed in two possible ways. One is that 
they represent potential gene­gene interactions, as GWA 
studies  have  identified  loci  underlying  susceptibility  to 
obesity and contributing to variation in obesity­related 
traits [71­78]. Here, body fat acts as a proxy for the effect 
of one or more of these variants. We have demonstrated 
examples of gene­gene interactions altering variation in 
T2DM­related quantitative traits in BetaGene [79,80]. A 
second  perspective  is  that  they  represent  the  effect  of 
environmental  or  lifestyle  exposures.  In  this  context, 
body fat could reflect net energy balance, such as the net 
caloric  balance  between  dietary  intake  (quantity  and 
composition) versus physical activity (type and intensity). 
Clearly,  additional  studies  will  be  required  to  better 
understand this complex interaction.
Clinical implications
The Human Genome Project was initiated to decode the 
‘book  of  life’  [81].  The  idea  that  the  genetic  code  for 
humans  could  be  deciphered  led  to  wide  speculation 
about how such information could be used to improve 
human health, given the genetic predisposition of many 
common complex diseases. However, the initial results 
from GWA studies raised questions regarding the utility 
Figure 2. Modification of the association between IGF2BP2 and 
insulin sensitivity by adiposity. Genotype-specific means (± SD) 
were computed for IGF2BP2 rs11705701 stratified by percentage 
body fat tertiles in participants of the BetaGene study. The lowest 
body fat tertile is shown on the left and the highest body fat tertile 
on the right. Insulin sensitivity decreases with each copy of the T2DM 
risk allele within the highest body fat tertile, but decreases within the 
lowest body fat tertile.
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variants showing association with complex phenotypes, 
such as GDM or T2DM, account for a relatively small 
fraction  of  the  known  heritability,  and  this  has  raised 
questions about whether gene variants can be used for 
genetic  prediction  [84].  The  study  by  Lauenborg  et  al. 
[51] and similar attempts to assess the predictive value of 
gene variants for T2DM [85,86] support the notion that 
gene variants alone may not be useful as predictive tools. 
However, as noted above, genetic prediction models may 
improve  once  the  functional  variants  are  known,  as 
suggested  by  a  recent  study  of  height  by  Yang  and 
colleagues [87]. One area in which genetic information 
may be useful is with regard to family history, which is a 
strong clinical predictor for many complex diseases such 
as GDM and T2DM. In many cases, patients are unaware 
of their family history or have biased information about 
it. In this situation, susceptibility variants may provide an 
accurate  reflection  of  the  genetic  burden  carried  by 
individuals  and,  in  conjunction  with  other  traditional 
clinical  variables,  may  provide  improved  disease  risk 
prediction.
Furthermore,  the  effect  sizes  of  loci  identified  so  far 
have  been,  for  the  most  part,  extremely  small  from  a 
clinical or epidemiological perspective. Individual T2DM 
susceptibility loci have had estimated odds ratios for risk 
of T2DM less than 1.5 and the proportion of variance 
explained  for  T2DM­related  quantitative  traits  has 
typically been less than 5%, with similar results observed 
for GDM [23,51,52,70] and related traits [51,52,66­68,70]. 
Skeptics  have  dismissed  the  practical  utility  of  gene 
variants in the face of such small effect sizes. However, as 
elegantly  noted  by  Hirschhorn  [83],  the  goal  of  GWA 
studies and the identification of genetic loci conferring 
susceptibility  to  disease  is  not  prediction  of  individual 
risk for disease, but biological discovery underlying the 
pathogenesis of these diseases. Indeed, one of the high­
lights of GWA studies, as noted above, is the discovery of 
the potential roles of MTNR1B and CRY2. MTNR1B was 
identified  as  contributing  to  T2DM  susceptibility  and 
variation in fasting glucose [45,49] and variation in insulin 
secretion [88], whereas CRY2 contributes to varia  tion in 
fasting  glucose  [49].  These  loci  highlight  the  potential 
importance  of  pathways  related  to  ‘clock’  genes  and 
circadian  rhythms  and  their  subsequent  regulation  of 
insulin  secretion  as  contributing  factors  in  the  patho­
genesis of T2DM.
Effect sizes of susceptibility loci should not be equated 
with  biological  relevance,  as  also  noted  by  Hirschhorn 
[83]. Two specific examples can be gleaned from among 
the T2DM susceptibility loci. The E23K variant (rs5219) 
in  KCNJ11,  the  ATP­sensitive  K+  channel  of  the 
pancreatic β­cell, is a T2DM susceptibility locus with an 
odds  ratio  of  1.18  [35].  KCNJ11  is  the  target  of  the 
sulfonylurea class of diabetes medications, highlighting 
the biological and clinical importance of this gene. The 
second  example  is  the  common  Pro12Ala  (rs1801282) 
variant  in  PPARG  (peroxisome  proliferator­activated 
receptor­γ, a nuclear transcription factor), which has an 
odds ratio of 1.27 for T2DM [34,89]. Thiazolidinediones 
are PPARG agonists that act as insulin­sensitizing agents 
and  are  used  to  treat  T2DM.  Studies  also  show  that 
treating at­risk individuals with thiazolidinediones may 
be effective in significantly reducing, or possibly prevent­
ing, development of future T2DM [90­94]. Thus, one can 
confidently state that both KCNJ11 and PPARG have high 
biological relevance for the pathogenesis and treatment 
of T2DM.
The one area in which genetic variation may be best 
leveraged for clinical care purposes is pharmacogenetics. 
The response to a drug ­ whether in terms of efficacy of 
treatment or adverse effects ­ and dosing of medications 
are not likely to be adversely affected by environmental 
exposures and tend to have large effect sizes [95]. There­
fore, some of the variability in response or dosing could 
be due to genetic variation. Pharmacogenetics in the area 
of diabetes is still in its infancy, although there have been 
studies examining KCNJ11 and sulfonylurea therapy for 
both rare [96,97] and common [98,99] variants and res­
ponse to thiazolidinedione therapy and candidate genes 
[100­103]. Results from pharmacogenetic studies could 
potentially  provide  physicians  with  a  powerful  tool  to 
adjust therapy appropriately for those individuals carry­
ing variants known to affect a given medication. Distefano 
and  Watanabe  have  recently  reviewed  the  pharmaco­
genetics of diabetes [104].
Gene­gene and gene­environment interactions are also 
likely to be helpful to the clinician in making therapeutic 
decisions. The situation with IGF2BP2 is a good example 
in which a physician may choose to pay closer attention 
to  the  adiposity  of  carriers  of  the  T2DM  risk  allele 
(Figure 2). Studies on the effects of physical activity on 
loci underlying susceptibility to obesity suggest similar 
clinical relevance when individuals whose genetic make­
up  is  resistant  to  the  effects  of  physical  activity  may 
require different interventions [105,106].
Conclusions
The study of the genetics underlying GDM has signifi­
cantly  lagged  behind  that  of  other  forms  of  diabetes. 
However, the dramatic gains made in understanding the 
genetic basis of both type 1 diabetes mellitus and T2DM 
in  the  past  few  years  have  important  implications  for 
GDM. Testing T2DM susceptibility loci in GDM case­
control samples provides evidence suggesting that, at a 
minimum, GDM and T2DM share common susceptibility 
loci.  Additional  studies  will  be  required  to  determine 
whether  there  are  susceptibility  loci  unique  to  GDM. 
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to  variation  in  GDM­related  quantitative  traits,  which 
has  implications  for  offspring.  Thus,  adverse  fetal  out­
comes associated with GDM or hyperglycemia in general 
may also have a genetic basis, as evidenced by the inter­
action between maternal and fetal GCK variants. Ultimately, 
a well­designed GWA or genome­wide sequen  cing study 
of GDM is needed to identify common variants of low 
effect and rare variants of large effect contributing to risk 
for GDM. In addition, there is increasing evidence that 
transcriptional regulation through chromatin modifica­
tion, such as methylation, acetylation, and so on, may be 
an  important  contributor  to  disease  risk.  Genomic 
approaches to assessing chromatin modification are only 
now being applied to complex diseases and could provide 
additional insights into the genetic contribution to risk 
for GDM and fetal outcomes.
Identification  of  loci  underlying  GDM  and  GDM­
related traits will illuminate the biological basis for GDM 
susceptibility and provide important clues for improved 
interventions. However, such new biological insights will 
require  additional  detailed  studies  before  they  can  be 
translated  into  the  clinical  setting.  Thus,  one  cannot 
expect  rapid  bench­to­bedside  translation  of  genetic 
findings.  However,  current  medical  training  is  paying 
insufficient attention to the coming transformative effect 
of  genetic  knowledge.  Individualized  medicine  has  not 
yet arrived and may never become a reality to the extent 
that has been previously hyped in the media. However, 
generalized gene­based response profiles to both lifestyle 
and pharmacological interventions may become a regular 
part of a physician’s arsenal to improve clinical care.
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